ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

ClinicalTrials.gov ID: NCT04884191

Public ClinicalTrials.gov record NCT04884191. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT04884191
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
CTI BioPharma
Industry
Enrollment
165 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 30, 2017
Primary completion
Sep 3, 2019
Completion
Sep 3, 2019
Last update posted
May 31, 2022

2017 – 2019

United States locations

U.S. sites
33
U.S. states
20
U.S. cities
27
Facility City State ZIP Site status
Mayo Clinic Hospital Phoenix Arizona 85054
City of Hope Duarte California 91010
USC Norris Comprehensive Cancer Center Los Angeles California 90033
UCLA Jonsson Comprehensive Cancer Center Los Angeles California 90095
Stanford Cancer Institute Stanford California 94305
Yale School of Medicine New Haven Connecticut 06520
Medical Faculty Associates, Inc. Washington D.C. District of Columbia 20037
Florida Cancer Specialists & Research Institute Fort Myers Florida 33901
Florida Cancer Specialists & Research Institute St. Petersburg Florida 33705
Florida Cancer Specialists & Research Institute West Palm Beach Florida 33401
Northwestern University Feinberg School of Medicine Chicago Illinois 60611
The University of Chicago Medical Center Chicago Illinois 60637
University of Kansas Cancer Center Westwood Kansas 66205
Ochsner Medical Center New Orleans Louisiana 70121
Saint Agnes Hospital Baltimore Maryland 21229
Dana-Farber Cancer Institute Boston Massachusetts 02215
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109
Washington University School of Medicine in St. Louis St Louis Missouri 63110
Hackensack University Medical Center Hackensack New Jersey 07601
Weill Cornell Medical College New York New York 10021
Icahn School of Medicine at Mount Sinai New York New York 10029
Columbia University New York New York 10032
Memorial Sloan-Kettering Cancer Center New York New York 10065
University of Rochester Rochester New York 14642
Duke University Hospital Durham North Carolina 27710
Cleveland Clinic Cleveland Ohio 44195
The Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Tennessee Oncology Nashville Tennessee 37203
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232
The University of Texas MD Anderson Cancer Center Houston Texas 77030
University of Texas Health Science Center at San Antonio School of Medicine San Antonio Texas 78229
University of Utah School of Medicine Salt Lake City Utah 84112
Fred Hutchinson Cancer Research Center Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04884191, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 31, 2022 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04884191 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →